(Q34823645)

4 August 2017

Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pylori (English)

1 reference

Helicobacter pylori infectious disease

4 August 2017

1 reference

1 reference

1 reference

Hyun Chul Lim

1

1 reference

4 August 2017

Yong Jae Lee

2

1 reference

4 August 2017

Byoungrak An

3

1 reference

4 August 2017

Seung Woo Lee

4

1 reference

4 August 2017

Yong Chan Lee

5

1 reference

4 August 2017

Byung Soo Moon

6

1 reference

4 August 2017

language of work or name

1 reference

18 September 2014

1 reference

4 August 2017

1 reference

4 August 2017

19

1 reference

4 August 2017

6

1 reference

4 August 2017

455-461

1 reference

Second and third line treatment options for Helicobacter pylori eradication

4 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284035

Antibiotic resistance in Helicobacter pylori strains and its effect on H. pylori eradication rates in a single center in Korea

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284035

A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication).

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284035

Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284035

Review article: rifabutin in the treatment of refractory Helicobacter pylori infection.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284035

A new look at anti-Helicobacter pylori therapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284035

Treatment of Helicobacter pylori infection 2011.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284035

Treatment of Helicobacter pylori infection 2010.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284035

Changes in 12-Year First-Line Eradication Rate of Helicobacter pylori Based on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284035

Helicobacter pylori "rescue" therapy after failure of two eradication treatments.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284035

Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284035

Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284035

Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284035

Rifampin and rifabutin resistance mechanism in Helicobacter pylori

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284035

Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284035

Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284035

Helicobacter pyloriInfection

8 July 2018

1 reference

Third-line rescue therapy for Helicobacter pylori infection

21 January 2018

1 reference

Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection

21 January 2018

1 reference

Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin

21 January 2018

1 reference

Rifabutin-based Helicobacter pylori eradication 'rescue therapy'.

21 January 2018

1 reference

Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients

21 January 2018

1 reference

In vitro post-antibiotic effect of fluoroquinolones, macrolides, beta-lactams, tetracyclines, vancomycin, clindamycin, linezolid, chloramphenicol, quinupristin/dalfopristin and rifampicin on Bacillus anthracis

21 January 2018

1 reference

Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin.

21 January 2018

1 reference

Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999.

21 January 2018

1 reference

European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori

21 January 2018

1 reference

Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection.

21 January 2018

1 reference

Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience.

21 January 2018

1 reference

High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study

21 January 2018

1 reference

Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284035

Resistance of Helicobacter pylori strains to antibiotics in Korea with a focus on fluoroquinolone resistance

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284035

Efficacy of 1-week proton pump inhibitor triple therapy as first-line Helicobacter pylori eradication regime in Asian patients: is it still effective 10 years on?

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284035

High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4284035

Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy

26 October 2018

1 reference

12 December 2020

Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy

1 reference

12 December 2020

Treatment of Helicobacter pylori

1 reference

12 December 2020

Severe neutropenia caused by recommended prophylactic doses of rifabutin

1 reference

12 December 2020

Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection

1 reference

12 December 2020

Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients

1 reference

12 December 2020

One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin

1 reference

12 December 2020

Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens

1 reference

12 December 2020

Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy

1 reference

12 December 2020

Costs of diagnosis and treatment of Helicobacter pylori infection: when does choosing the treatment regimen based on susceptibility testing become cost effective?

1 reference

12 December 2020

Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures

1 reference

12 December 2020

Identifiers

DOI

10.1111/HEL.12147

1 reference

4 August 2017

1 reference

4 August 2017

1 reference